Effects of discontinuation of dasatinib or nilotinib in patients with chronic phase or accelerated phase chronic myeloid leukemia
Latest Information Update: 21 Nov 2019
At a glance
- Drugs Dasatinib (Primary) ; Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms STOP 2G-TKI Study
- 13 Nov 2019 Results published in the Blood
- 06 Nov 2019 Updated results (Data as of July 1, 2019, n=104) from the trial assessing risk of relapse using post-baseline information during follow-up released at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem 2019).
- 15 Dec 2016 New trial record